We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ISRG's International Weakness a Temporary Drag or Structural Risk?
Read MoreHide Full Article
Key Takeaways
ISRG Q1 2026 shows strong OUS procedure growth but weakness in China and Japan.
China faces pricing pressure, slow tenders and local competition, hurting placements.
Japan delays tied to hospital budgets, but reimbursement gains may revive demand.
Intuitive Surgical’s (ISRG - Free Report) first-quarter 2026 performance reflects a nuanced international picture — strong overall OUS (outside U.S.) procedure growth, but with emerging pockets of weakness, particularly in China and Japan. While international markets remain a key pillar of long-term expansion, recent trends highlight increasing exposure to policy and macro-driven variability.
China remains the most prominent source of near-term pressure. Management pointed to slower tender activity, intensified pricing pressure and rising competition from domestic players, all of which are adversely impacting system placements and near-term growth visibility. The tender-based procurement system inherently introduces volatility, and the growing preference for local manufacturers further complicates Intuitive Surgical’s positioning. These dynamics suggest that China may transition into a structurally more competitive and lower-margin market, even if long-term procedure demand remains intact.
In Japan, the challenge is less about competition and more about capital constraints within hospital systems, which are delaying system adoption. However, the outlook here appears more constructive. Management highlighted an improving reimbursement environment, which could gradually unlock demand and support future procedure growth. This suggests that Japan’s weakness is more cyclical than structural.
Outside these two markets, international growth remains robust, supported by expanding clinical adoption, training infrastructure and broader access to robotic-assisted surgery. This reinforces the view that global demand fundamentals are intact.
Overall, Intuitive Surgical’s international weakness appears partly temporary and partly structural. While Japan’s headwinds are likely cyclical, China presents a more complex mix of policy risk and competitive intensity. The company’s ability to navigate pricing, local competition and capital constraints will be critical in determining whether international markets remain a consistent growth driver or a source of ongoing volatility.
Peer Updates
DexCom (DXCM - Free Report) delivered strong international performance, with revenue outside the United States growing 18% on a reported basis (15% organic) in the fourth quarter of 2025, driven by expanding CGM adoption across Europe, particularly in markets like Germany, the United Kingdom and France. Growth is being fueled by broader reimbursement access, especially in type 2 diabetes, and a tiered product portfolio strategy tailored to local market dynamics. However, challenges persist, including tiered reimbursement systems and slower coverage expansion in certain regions. DexCom is addressing these through increased awareness, product localization and upcoming launches like Stelo internationally, positioning DexCom to sustain double-digit international growth.
Glaukos (GKOS - Free Report) is also expanding internationally, with its glaucoma franchise delivering 18% reported growth (13% constant currency), supported by continued adoption of MIGS technologies and infrastructure scaling. Glaukos is driving growth through physician training, market development and broader access initiatives, particularly for its iStent portfolio. However, international markets face competitive headwinds from new product trialing, which are expected to persist into 2026 and may moderate growth rates. Despite this, Glaukos’ differentiated pipeline and recent European launches, such as iStent infinite, provide incremental tailwinds, supporting long-term international expansion.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 17.6% so far this year compared with an 15% decline for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 43.35, above the industry average. But it is still lower than its five-year median of 70.45. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies an 15.7% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Shutterstock
Is ISRG's International Weakness a Temporary Drag or Structural Risk?
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) first-quarter 2026 performance reflects a nuanced international picture — strong overall OUS (outside U.S.) procedure growth, but with emerging pockets of weakness, particularly in China and Japan. While international markets remain a key pillar of long-term expansion, recent trends highlight increasing exposure to policy and macro-driven variability.
China remains the most prominent source of near-term pressure. Management pointed to slower tender activity, intensified pricing pressure and rising competition from domestic players, all of which are adversely impacting system placements and near-term growth visibility. The tender-based procurement system inherently introduces volatility, and the growing preference for local manufacturers further complicates Intuitive Surgical’s positioning. These dynamics suggest that China may transition into a structurally more competitive and lower-margin market, even if long-term procedure demand remains intact.
In Japan, the challenge is less about competition and more about capital constraints within hospital systems, which are delaying system adoption. However, the outlook here appears more constructive. Management highlighted an improving reimbursement environment, which could gradually unlock demand and support future procedure growth. This suggests that Japan’s weakness is more cyclical than structural.
Outside these two markets, international growth remains robust, supported by expanding clinical adoption, training infrastructure and broader access to robotic-assisted surgery. This reinforces the view that global demand fundamentals are intact.
Overall, Intuitive Surgical’s international weakness appears partly temporary and partly structural. While Japan’s headwinds are likely cyclical, China presents a more complex mix of policy risk and competitive intensity. The company’s ability to navigate pricing, local competition and capital constraints will be critical in determining whether international markets remain a consistent growth driver or a source of ongoing volatility.
Peer Updates
DexCom (DXCM - Free Report) delivered strong international performance, with revenue outside the United States growing 18% on a reported basis (15% organic) in the fourth quarter of 2025, driven by expanding CGM adoption across Europe, particularly in markets like Germany, the United Kingdom and France. Growth is being fueled by broader reimbursement access, especially in type 2 diabetes, and a tiered product portfolio strategy tailored to local market dynamics. However, challenges persist, including tiered reimbursement systems and slower coverage expansion in certain regions. DexCom is addressing these through increased awareness, product localization and upcoming launches like Stelo internationally, positioning DexCom to sustain double-digit international growth.
Glaukos (GKOS - Free Report) is also expanding internationally, with its glaucoma franchise delivering 18% reported growth (13% constant currency), supported by continued adoption of MIGS technologies and infrastructure scaling. Glaukos is driving growth through physician training, market development and broader access initiatives, particularly for its iStent portfolio. However, international markets face competitive headwinds from new product trialing, which are expected to persist into 2026 and may moderate growth rates. Despite this, Glaukos’ differentiated pipeline and recent European launches, such as iStent infinite, provide incremental tailwinds, supporting long-term international expansion.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 17.6% so far this year compared with an 15% decline for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 43.35, above the industry average. But it is still lower than its five-year median of 70.45. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies an 15.7% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.